Are serial bone scans useful for the follow-up of clinically localized, low to intermediate grade prostate cancer managed with watchful observation alone?

BJU International

Volumn 91, Issue 7, 2003, Pages 613-617

  Yap, B K ^a   Choo, R ^a,b   Deboer, G ^a   Klotz, L ^a   Danjoux, C ^a   Morton, G ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

Prostate cancer; PSA; Serial bone scan; Watchful observation

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CANCER LOCALIZATION; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; FOLLOW UP; HEALTH CARE COST; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; TREATMENT PLANNING;

AGED; AGED, 80 AND OVER; BONE NEOPLASMS; COHORT STUDIES; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TECHNETIUM TC 99M MEDRONATE;

EID: 0037907248     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2003.04169.x     Document Type: Article

References (21)

1. McGregor B, Tulloch AGS, Quinlan MF et al. The role of bone scanning in the assessment of prostatic carcinoma. Br J Urol 1978; 50: 178-81
2. Gerber G, Chodak GW. Assessment of value of routine bone scans in patients with newly diagnosed prostate cancer. Urology 1991; 37: 418-22
3. Schaffer DL, Pendergrass HP. Comparison of enzyme, clinical, radiographic and radionuclide methods of detecting bone metastases from carcinoma of the prostate. Radiology 1976; 121: 431-4
4. Oesterling JE, Martin SK, Bergstralh EJ et al. The use of prostate specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 1993; 269: 57-60
5. Kemp PM, Maguire GA, Bird NJ. Which patients with prostate carcinoma require a staging bone scan? Br J Urol 1997; 79: 611-4
6. Levran A, Gonzalez JA, Diokno AC et al. Are pelvic computed tomography, bone scan and pelvic lymphadenectomy necessary in the staging of prostatic cancer? Br J Urol 1995; 75: 778-81
7. Rudoni M, Antonini G, Favro M et al. The clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer. Eur J Nucl Med 1995; 22: 207-11
8. Chybowski FM, Keller JJ, Bergstralh EJ et al. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: Prostate specific antigen is superior to all other clinical parameters. J Urol 1991; 145: 313-8
9. Gleave ME, Coupland D, Drachenberg D et al. Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer. Urology 1996; 47: 708-12
10. Choo R, Klotz L, Danjoux C et al. Feasibility study. Watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on PSA, histological and/or clinical progression. J Urol 2002; 167: 1664-9
11. Choo R, DeBoer G, Klotz L et al. PSA doubling time of prostate carcinoma managed with watchful observation alone. Int J Radiat Oncol Biol Phys 2001; 50: 615-20
12. Lehr JE, Pienta KJ. Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line. JNCI 1998; 90: 118-23
13. Murphy GP, Natarajan N, Pontes JE et al. The national survey of prostate cancer in the United States by the American College of Surgeons. J Urol 1982; 127: 928-34
14. Veterans Administration Cooperative Urologic Research Group. Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 1967; 124: 1011-7
15. Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistics, 1994. CA Cancer J Clin 1994; 44: 7-26
16. Brawer MK, Chemer MP, Beatie J, Buchner DM, Vessella RL, Lange PH. Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992; 147: 841-8
17. Catalona WJ, Smith DS, Ratliff TL et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. New Eng J Med 1991; 324: 1156-61
18. Wymenga LFA, Boomsma JHB, Groenier K et al. Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphatase. BJU Int 2001; 88: 226-30
19. Medical Research Council Prostate Cancer Working Party Investigators Working Group. Immediate versus deferred treatment for advanced prostate cancer: initial results of the Medical Research Council trial. Br J Urol 1997; 79: 235-46
20. Chodak GW, Thisted RA, Gerber GS et al. Results of conservative management of clinically localized prostate cancer. New Eng J Med 1994; 330: 242-8
21. Oesterling JE. Using prostate-specific antigen to eliminate unnecessary diagnostic tests: significant worldwide economic implications. Urology 1995; 46 (Suppl. 3A): 26-33